IL6 and chronic kidney disease: The RESCUE (Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition) study investigated ziltivekimab, an IL-6 ligand monoclonal antibody, in individuals with chronic kidney disease (CKD), elevated hsCRP, and high cardiovascular risk [27].